Delivery Order SPE2DB20D3103-SPE2DB25FQ3X4
- Not listed
- The Defense Logistics Agency awarded a $6,704.88 delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin injection used in medical and therapeutic applications. This firm fixed price delivery order, issued on August 7, 2025, represents a competitively awarded, non-set-aside contract with an ultimate completion date of August 28, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,676.22 delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a child contract under AmerisourceBergen's larger pharmaceutical supply agreement. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $8,381.10 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin-based therapeutic product used for medical applications. This non-set-aside, competitively awarded contract is issued under a firm fixed price structure with an ultimate completion date of September 19, 2025. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $14.4K delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used in medical and therapeutic applications. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by October 7, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product commonly used for therapeutic and cosmetic applications in military and veteran healthcare settings. This firm fixed-price delivery order, valued at $2,514.33, was competitively awarded without set-aside provisions and is scheduled for completion by September 17, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes, with a ceiling value of $11,174.80. The contract, awarded on June 26, 2025, with an ultimate completion date of July 18, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,676.22 to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This firm fixed-price delivery order, issued on March 18, 2025, is scheduled for completion by April 8, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation,...
- The Defense Logistics Agency awarded a $16,762.20 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. The contract was competitively awarded without set-aside designation and is scheduled for completion by May 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 delivery order for Xeomin 100 Unit Vials, a botulinum toxin product used for medical purposes. This competitive award, issued on August 25, 2025, carries an ultimate completion date of September 16, 2025, and utilizes firm fixed pricing with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under the company's...
- The Defense Logistics Agency (DLA) awarded a $30,878.12 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 200-unit vials of Xeomin, a botulinum toxin product used for therapeutic and cosmetic medical applications. This non-set-aside contract, issued on September 17, 2025, with completion targeted for October 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX). The IDC, valued at...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ3X4Delivery Order
The Defense Logistics Agency awarded a $27,937 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100-unit vials of Xeomin, a botulinum toxin product used for medical and therapeutic purposes. The contract, issued on September 18, 2025, with an ultimate completion date of October 9, 2025, represents a non-competitive, direct fulfillment order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary pharmaceutical distribution operations. This delivery order falls under AmerisourceBergen's comprehensive $999.999 billion Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The company's consistent receipt of competitively awarded, non-set-aside contracts demonstrates its established capability to meet federal pharmaceutical procurement requirements at varying scales.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 9/18/25 |